Skip to main content
. 2020 Apr 17;9(1):1752563. doi: 10.1080/2162402X.2020.1752563

Table 2.

Univariate and multivariate analysis of disease-free survival in patients with CRC.

  Univariate analysis
Multivariate analysis
Variables HR (95% CI) P HR (95% CI) P
Sex (male vs. female) 1.581 (0.832–3.004) 0.162    
Age (≥ 60 vs. < 60) 1.158 (0.618–2.171) 0.647    
Primary tumor (right- vs. left-sided colon vs. rectum) 1.072 (0.745–1.543) 0.707    
Histology (poorly vs. well/moderate) 1.000 (0.518–1.931) 0.999    
T stage (4 vs. 3, 2, 1) 2.014 (1.127–3.599) 0.018a 2.139 (1.192–3.838) 0.011a
N stage (2 vs. 1 vs. 0) 1.387 (0.900–2.138) 0.139    
TNM stage (III, IV vs. II) 1.357 (0.689–2.672) 0.378    
Chemotherapy regimen (CAPOX, Capecitabine vs. FOLFOX) 0.688(0.372–1.273) 0.234    
Duration of chemotherapy (> 20 weeks vs. < 20 weeks) 0.556(0.312–0.992) 0.047a 0.566 (0.317–1.013) 0.055
Treatment (CIK vs. control) 0.399 (0.215–0.741) 0.004a 0.399 (0.214–0.743) 0.004a

HR, Hazard ratio; CI, confidence interval; CRC, colorectal cancer; CAPOX, Capecitabine + Oxaliplatin; FOLFOX, Oxaliplatin + 5-fluorouracil; CIK, cytokine-induced killer cell.

aP value < 0.05